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Purpose: Recurrent platinum-resistant ovarian cancer has no curative options, necessitating the development of
novel treatments, including immunotherapy.
Rationale: Patient-derived T cells can be genetically modified to express chimeric antigen receptors (CARs)
specific to tumor-associated antigens in an HLA-independent manner, with promising preclinical results. MUC16ecto
is highly expressed on most epithelial ovarian carcinomas but at low levels on normal tissues, offering an excellent
immunotherapeutic target for this cancer. CAR T cells further modified to secrete IL-12 show enhanced cytotoxicity,
persistence, and modulation of the tumor microenvironment.
Design: We propose a dose escalation phase I clinical trial for patients with recurrent MUC-16ecto+ ovarian cancer
to test the safety of intravenous and intraperitoneal administration and the preliminary efficacy of autologous IL-12
secreting, MUC-16ecto CAR T cells containing a safety elimination gene.
Innovation: This trial targets MUC-16ecto, a novel and promising tumor-associated antigen. This will be the first time
CAR T cells are injected intraperitoneally directly into the site of the tumor within the abdomen in humans. Furthermore,
the ability of genetically modified cells to secrete IL-12 will potentially enhance CAR T cell persistence and modulate
the tumor microenvironment. For safety purposes, an elimination gene has been incorporated into the CAR T cells to
mitigate any on-target, off-tumor or other unforeseen toxicity.
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CAR T cell therapy in ovarian cancer
Ovarian cancer is the second most common gynecologic
malignancy in the United States, with 21,290 projected
new cases in 2015, and the most lethal gynecologic
malignancy, with 14,180 estimated deaths in the same
year [1]. Due to the insidious nature of this disease, the
majority of patients with ovarian cancer are diagnosed
with advanced disease due to intraperitoneal spread and
often the presence of distant metastases (International
Federation of Gynecology and Obstetrics [FIGO] stage
III/IV disease). The standard of care for these patients
includes cytoreductive surgery, when feasible, followed by* Correspondence: brentjer@mskcc.org
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unless otherwise stated.combination platinum- and taxane-based chemotherapy
[2-4]. Despite the fact that up to 75% of patients
achieve a good clinical response following initial therapy,
almost all will ultimately relapse and eventually develop
chemotherapy-refractory disease [5]. For this reason, novel
therapeutic approaches are urgently needed.
Epithelial ovarian cancer appears well suited for the
investigation of immunotherapeutic strategies, such as
adoptive T cell therapy, given that the presence of
tumor infiltrating lymphocytes (TILs) correlates positively
with patient survival [6,7]. Chimeric antigen receptors
(CARs) are artificial cell receptors that allow T cells to
target a tumor-associated antigen (TAA). We and others
have developed CAR genes in order to generate genetically
modified tumor-specific T cells [8]. These CARs combine
the targeted antigen specificity provided by monoclonal
antibodies (mAbs) with the cytotoxic anti-tumor effects of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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TAAs in a human leukocyte antigen (HLA)-independent
manner. Therefore, the same receptor may be applied
to all patients, independent of HLA type or level of
HLA expression by the tumor cell. Since the modified T
cells are autologous to the patient, the risk of unforeseen
graft-versus-host disease (GVHD) is largely averted.
Overcoming a hostile tumor environment is one of the
major challenges facing adoptive T cell therapy. Various
factors that cause dysfunction in TILs, such as regulatory
T cells (Tregs) and inhibitory cytokines, can also negatively
regulate in vivo persistence and antitumor activity of CAR
Tcells [9]. Though the infusion of CAR Tcells can increase
the proportion of functional T cells relative to suppressive
Tregs, the rise in number alone may not be sufficient to
overcome the inhibition. To this end, CAR T cells can be
modified to secrete stimulatory factors that promote a pro-
ductive anti-tumor immune response, even in the presence
of suppressive Tregs and other inhibitory elements.
Target, addition of IL-12 gene, elimination gene
To create an effective CAR T cell, an appropriate target
needs to be identified. The ovarian cancer antigen,
MUC16, is over-expressed by a majority of ovarian cancers
[10]. The recent isolation of the gene encoding MUC16 by
the laboratory of Kenneth Lloyd [11] allowed for the
characterization of MUC16 as a glycosylated mucin.
Significantly, the full-length glycoprotein consists of a large
cleaved and released domain termed CA-125 consisting of
multiple repeat sequences, each containing a disulfide loop
of 19 amino acids, followed by a retained cytoplasmic
domain, MUC16ecto, which includes a residual non-
repeating extracellular fragment, a transmembrane domain,
and a cytoplasmic tail containing a phosphorylation site
(Figure 1). CA-125, an FDA-approved tumor marker for







Figure 1 Schematic diagram of MUC-16 structure.women with epithelial ovarian cancer. To date, all reported
mAbs to MUC16 bind to epitopes present on the released
fraction of the glycoprotein, with none known to bind to
the retained extracellular fraction. Since the MUC16ecto
fraction is retained on the cell surface and expressed only
at low levels on normal tissue, including the uterus,
fallopian tubes, ovaries and corneal surface of the eye,
it is a highly attractive target for CAR-based adoptive
T cell therapy [12-14]. A hybridoma that generates a
mAb specific to the extracellular retained fraction of
the MUC16 antigen (MUC16ecto) has been utilized to cre-
ate a CAR specific to MUC16ecto (4H11-28z), which in turn
can be utilized to engineer autologous T cells targeted to
the retained, surface-exposed antigen.
Though an appropriate target antigen is necessary, it
may not be sufficient in creating an effective CAR
against a solid tumor given the inhibitory tumor
microenvironment. Therefore, we have armored the
CAR with the ability to secrete interleukin-12 (IL-12),
which can modulate the negative effects of the tumor
microenvironment. IL-12 is a heterodimeric inflammatory
cytokine expressed by activated antigen-presenting cells
(APCs), neutrophils, and macrophages [15]. IL-12 is a
potent inducer of a Th1 CD4+ T cell response and serves
as a “signal 3” in concert with T cell receptor (TCR)
activation (signal 1) and CD28 co-stimulation (signal 2) to
CD8+ T cells, resulting in optimized clonal expansion and
effector function [16]. IL-12 further induces proliferation
and cytotoxic activity of natural killer (NK) cells and gen-
erates anti-tumor activity through effector cell production
of cytokines, including interferon-gamma (INF-γ), which
in turn up-regulates Fas (CD95) and FasL on tumor cells.
More significantly, IL-12 has been shown to modulate the
hostile tumor microenvironment through multiple mecha-
nisms, including reactivation of anergic TILs, inhibition of
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transforming growth factor beta (TGF-β) secretion by
tumor-associated macrophages (TAMs) [17-19]. We have
previously demonstrated in preclinical models that
CAR-targeted T cells traffic to systemic sites of tumor
involvement [20]. To this end, we predict that infusion of
CAR T cells further modified to secrete IL-12 will result in
targeted secretion of this cytokine within the tumor
microenvironment. As a result, we further predict en-
hanced in vivo persistence and anti-tumor activity of
these T cells, now resistant to inhibition by Tregs,
with subsequent reactivation of anergic endogenous
tumor-targeted T cells as well as IL-12 induced re-
cruitment and activation of the innate tumor-targeted
NK cells (Figure 2).
If on-target, off-tumor or unforeseen toxicities are
encountered, the addition of a “safety switch” permits
the removal of aberrant genetically modified T cells
in vivo [21]. In preclinical models, the administration
of cetuximab, an anti-EGFR (epidermal growth factor
receptor) mAb that binds to the truncated EGFR
(EGFRt) protein expressed by the CAR-modified T
cells, induced death of EGFRt-transduced T cells via
multiple mechanisms, including antibody-dependent
cellular cytotoxicity and complement-mediated cytotoxicity
[21]. In a published study by Wang et al., greater than 50%
of EGFRt+ T cells were killed in vitro within 1 hour after
exposure to cetuximab; in vivo, NOD/scid mice engrafted
with EGFRt+ T cells were cleared of those cells after
4–6 days of daily administration of cetuximab 1 mg
intraperitoneally [21]. The use of cetuximab to elim-
inate EGFRt+ CAR-modified T cells is approved under
BB-IND-15829.
Preclinical data using tricistronic vector indicates that
4H11-28z/fIL-12/EFGRt CAR T cells show enhanced
proliferation and increased IFN-γ secretion compared to
control CAR T cells in vitro [22]. In mouse models using
human ovarian cancer xenografts, IL-12 secreting CARFigure 2 Secretion of IL-12 by CAR-modified T cells may improve
cytotoxicity of CAR+ T cells and reverse anergy in tumor
infiltrating lymphocytes.T cells exhibit enhanced anti-tumor efficacy exemplified
by increased survival, prolonged persistence of T cells, and
higher systemic IL-12 and IFN-γ levels [22]. The addition
of cetuximab causes >60% CAR T cell death after only
4 hours in vitro, while in vivo, the addition of cetuximab
to mice injected with 4H11-28z/fIL-12/EFGRt CAR T cells
shows decreased levels of IL-12 and IFN-γ nearly to base-
line [22]. These promising preclinical results validate the
function of the three components of the CAR.
Trial design
This is a phase I clinical trial testing the safety of intraven-
ous (IV) and intraperitoneal (IP) infusion (with or without
prior cyclophosphamide chemotherapy) of genetically
modified autologous T cells in patients with recurrent
MUC16ecto+ ovarian, fallopian tube, or primary peritoneal
cancer. These autologous T cells will be genetically
engineered to express the 4H11-28z CAR targeting
the MUC16ecto antigen, secrete IL-12, and express
EGFRt elimination vector (4H11-28z/fIL-12/EFGRt).
Patients with recurrent high-grade serous ovarian, primary
peritoneal or fallopian tube carcinoma shown to express
MUC16ecto antigen confirmed by immunohistochemistry
(IHC) analysis of banked (paraffin embedded) or freshly
biopsied tumor will potentially be eligible for the study. A
scoring system of 0–5 will be applied to MUC16ecto expres-
sion as described by Dharma et al. that takes into account
percentage of cells, intensity, and pattern of staining [23].
Only moderate to strong immunoreactive scores (3–5) will
be considered positive, with a score of 3 described as
51-75% strong or 51-100% weak, 4 as 76-99% strong,
and 5 as 100% strong staining. All patients will have
received prior chemotherapy for recurrence, with a
maximum of five prior lines of chemotherapy permitted.
Patients with other active malignancies, a life expect-
ancy of <3 months, or a Karnofsky Performance Status
(KPS) score <70% at the time of planned treatment will be
ineligible.
This is a standard phase I dose-escalation trial. Cohorts of
3–6 patients will be infused with escalating doses of modi-
fied T cells to establish the maximum tolerated dose
(MTD). There are four planned dose levels: 3 × 105,
1 × 106, 3 × 106, and 1 × 107 4H11-28z/fIL-12/EFGRt
T cells/kg. Cohorts I and II will be treated with 3 × 105
4H11-28z/fIL-12/EFGRt T cells/kg but patients in cohort II
will also receive lymphodepleting cyclophosphamide.
Cohorts II-V will receive escalating doses of the modified
T cells following pretreatment with cyclophosphamide.
Lymphodepleting cyclophosphamide dosed at 750 mg/m2
will be administered 2–4 days prior to the initial T
cell infusion. A standard 3 + 3 dose escalation schema
will be followed. If the first dose level exceeds the
MTD, a subsequent cohort of 3–6 patients will be treated
at the −1 dose level of 1 × 105 4H11-28z/fIL-12/EFGRt
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phosphamide (cohort -I) (Table 1).
Intraperitoneal administration of CAR T cells
Studies in ovarian cancer have shown that chemotherapy
regimens that incorporate IP delivery of treatment are
superior to those of IV administration alone, which is
rational given that the predominant site of ovarian
cancer is within the peritoneal cavity. More specifically,
several multicenter randomized clinical trials demon-
strated increased progression-free and overall survival
for IV/IP versus IV administration of chemotherapy. IV/IP
chemotherapy is now considered standard of care in the
first-line treatment of optimally debulked stage III ovarian
cancer [24]. It is therefore reasonable to hypothesize that
IP delivery of modified CAR T cell therapy may also lead
to improved efficacy.
In this trial, we plan to deliver CAR T cell therapy via IV
and IP routes. There is no previous human experience with
IP delivery of CAR T cells, since the majority of CAR T cell
therapies to date has been in patients with hematological
malignancies; hence, we must rely on preclinical data from
our mouse models. In Chekmasova et al. [25], SCID-Beige
mice injected IP with human OV-CAR3(MUC-CD) tumor
cells and then treated either IV or IP with 4H11-28z T cells
showed statistically enhanced survival compared to control
mice (who were either untreated or treated with CAR T
cells targeting the irrelevant antigen CD19). However,
IV- and IP-treated mice exhibited statistically equivalent
antitumor efficacy using the second generation CAR
(4H11-28z). We have further compared IV versus IP
administration using IL-12 secreting CAR T cells and have
found that while both groups of mice have extended
survival, IP administration has improved survival com-
pared to the IV route [22]. In this experiment, both groups
of mice were initially injected with ovarian tumor (SKOV3
expressing MUC16ecto, 1 × 107, IP) followed by CAR Tcell
injection either IP or IV (14 days later, 2.5 × 106 CAR T
cells). In this mouse model, GFP-luciferase positive tumor
is injected IP, and subsequent bioluminescence imaging
confirms that the engrafted tumors are restricted to the
peritoneal cavity. These preclinical studies indicate that IP
injections of CAR T cells are more efficacious than IV
alone. Although the administration of IP chemotherapy inTable 1 4H11-28z/fIL-12/EFGRt T cell dose escalation
Cohort Dose level Cyclophosphamide dose
-I −1 None
I 1 None
II 1 750 mg/m2
III 2 750 mg/m2
IV 3 750 mg/m2
V 4 750 mg/m2ovarian cancer patients reduces the risk of recurrence
within the abdomen, these patients frequently have
recurrences outside of the abdominal cavity [26,27].
Therefore, in our study, in addition to IP administration
of the modified T cells we have also included IV dosing in
order to address the extraperitoneal sites of disease.Objectives and endpoints of the phase I clinical trial
The primary objective of this study is to assess the safety of
IV and IP infusion of autologous 4H11-28z/fIL-12/EFGRt
T cells with or without prior high-dose cyclophosphamide.
The secondary objectives are to assess the anti-tumor
efficacy and the in vivo persistence of adoptively trans-
ferred 4H11-28z/fIL-12/EFGRt T cells and finally to assess
whether infusion of modified T cells enhances expansion
of endogenous tumor-targeted T cells.Regimen
Patients with recurrent high-grade serous ovarian cancer
will be offered a screening informed consent to test their
tumor for the expression of MUC16ecto. If MUC16ecto
positivity is confirmed by IHC (score 3–5, as described
above under Trial Design), then patients will have a
leukapheresis product obtained from peripheral blood.
The leukapheresis product will be washed to remove
excess platelet and red blood cell contamination and
then frozen. In the treatment phase of the study, the
leukapheresis product will be thawed and washed.
Subsequently, CD3+ T cells will be isolated from the
thawed leukapheresis product by magnetic separation
using CD3/CD28 beads in the Cell Therapy and Cell
Engineering Facility at MSKCC. Activated T cells will
be retrovirally transduced with the MUC16ecto specific
4H11-28z chimeric receptor, IL-12 gene, and EGFRt elim-
ination gene and further expanded using an established
CD3/CD28 bead expansion protocol.
Peripheral T cells will likely be quantitated by flow
cytometry analysis using CD3-specific antibody to verify
that a sufficient cell number is obtained. Although we
anticipate achieving the desired T cell dose through our
proposed transduction/expansion protocol for most patient
samples, in cases where at least 50% of the planned T cell
dose is not achieved following T cell stimulation, the4H11-28z/fIL-12/EFGRt T cell dose Number of patients
1 × 105 cells/kg 3-6 patients
3 × 105 cells/kg 3-6 patients
3 × 105 cells/kg 3-6 patients
1 × 106 cells/kg 3-6 patients
3 × 106 cells/kg 3-6 patients
1 × 107 cells/kg 3-6 patients
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by the next enrolled subject for that cohort.
When the modified T cells are ready for administration,
all patients will have an IP catheter placed prior to T cell
infusion. Patients will be admitted as inpatients to our
hospital prior to their first infusion of CAR T cells and will
remain hospitalized until at least 2 days after the second
infusion of CAR T cells. The first cohort of patients to be
treated, and the first patient treated in each subsequent
cohort, will be admitted to the intensive care unit (ICU);
subsequent patients may be admitted to the gynecologic
medical oncology inpatient service (subject to the clinical
judgment of the treating physician).
Patients treated in cohorts II-V will receive a single dose
of lymphodepleting cyclophosphamide (750 mg/m2 IV)
chemotherapy 2 to 4 days prior to initiating treatment
with modified T cells. Prior to infusion, the transduced T
cells will be quality tested for number, purity, viability, and
sterility. The following T cell release criteria must be met,
including viability >80%, CD3+ ≥95% with a minimum of
50% of planned T cell dose achieved according to CAR
and EGFRt co-expression, and the infused T cell popula-
tion must have a transduced fraction of >20% based on
flow cytometric analysis of expanded T cell population.
Furthermore, the average vector copy number in the
transduced T cells will be determined by real time PCR
before infusion and will need to be in the range of 0.25 to
4 copies per cell, and PCR will be used to ensure the
absence of replication competent retrovirus in the
transduced T cells. All patients will receive 50% of
the genetically modified T cell dose intravenously. Patients
will be closely monitored for toxicities. One to 3 days later,
the remaining dose of T cells will be administered as an IP
infusion (Figure 3). At least 3 patients will be treated at
dose level 1, with an accrual of no more than 2 patients
per month within each dose level. At least one week will
elapse between treatments of each patient enrolled.
All patients treated in the preceding cohort will be
observed for a minimum of 4 weeks from the day of

















Figure 3 Treatment schema.cohort occurs. In light of a significant risk for neutro-
penia (ANC ≤ 1,000/mm3) following cyclophosphamide
therapy, patients treated with cyclophosphamide may be
treated with growth factor support at the discretion of
the investigators (either a single subcutaneous injection
of pegfilgrastim or 3 consecutive days of subcutaneous
filgrastim).
Blood samples will be obtained from all patients prior
to and following treatment to assess toxicity, therapeutic
effects, and survival of the genetically modified T cells.
Post-treatment blood samples will be collected at
approximately 1 hr, 1 day, and at 1, 2, 3, 4, 5, 6, 7,
8 and 12 weeks post T cell infusion, then monthly
thereafter until 1 year, then yearly thereafter up to
15 years post T-cell infusions. If technically feasible,
patients’ ascitic fluid may also be sampled prior to
cyclophosphamide or T cell therapy (whichever comes
first), as well as during follow-up. Patients will have CT
scans at approximately 6 weeks, 3 months, 6 months,
9 months and 12 months after T cell infusion, and
thereafter if clinically indicated.
Management of severe cytokine release syndrome (sCRS)
In ongoing trials of CAR-modified T cell therapy for
patients with hematological malignancies, some patients
with B cell acute lymphoblastic leukemia (B-ALL) who
received modified T cells with a different construct
(19-28z, which targets the CD19 antigen found on B
cells) developed severe cytokine release syndrome (sCRS),
which is characterized by persistent fever, elevation of
serum cytokines, and clinical toxicities [28]. All cases of
sCRS were observed in patients with morphologic B-ALL
at the time of CAR-modified T cell infusion, and we
anticipate the potential for similar toxicity for this
ovarian cancer CAR T cell trial. Severe CRS is defined
by the presence of one of the following clinical and
laboratory parameters: (1) hypotension defined as systolic
blood pressure <90 mmHg refractory to IVF challenge or
requiring vasopressors, (2) respiratory distress/hypoxia
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troponin and/or EKG changes, and (4) seizure clinically
suspected and/or documented on EEG. Based on current
ongoing trials with CAR T cells using the 19-28z con-
struct, our experience is that sCRS manifests with fevers,
hypotension, and CNS toxicity occurring at approximately
day 4–5 post CAR T cell infusion [29].
We also anticipate potential toxicities related to IL-12,
but these toxicities are more typically related to liver
dysfunction and occur 1–3 days post-infusion [30,31].
Patients will be closely monitored, initially in the ICU, and
also have regular blood work including assessments of hep-
atic and renal function. We will also monitor C-reactive
protein (CRP) and cytokine levels (EGF, FGF-2, Eotaxin,
TGF-a, G-CSF, Flt-3 L, GM-CSF, FRACTALKINE, IFN-a2,
IFN-g, GRO, IL-10, MCP-3, IL-12p40, MDC, IL-12p70,
IL-13, IL-15, sCD40L, IL-17, IL-1ra, IL-1a, IL-9, IL-1b, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1a,
MIP-1b, TNF-a, TNF-b, and VEGF). Our experience from
the ongoing clinical trial using CARs to treat patients with
leukemia has shown CRP levels to be useful in CRS [32].
Thirdly, we have a comprehensive algorithm that outlines
the proposed treatment for patients who encounter CAR T
cell toxicity including tocilizumab, cetuximab, and steroids.Criteria for sCRS:
• Hypotension (SBP< 90) refractory to IVF challen
• Respiratory distress/hypoxia requiring increasin
• Acute coronary syndrome with positive troponin
• Seizure, clinically suspected and/or documented
Tocilizumab8
WorseningCRS within 12 hrs. (def. as above)
Cetuximab 400mg/m2 IV once





For patients who received IP CAR+
WorseningCRS within 12 hours
• Increasing vasopressors dose OR
• Increasing ventilatory support OR
• Persistent seizure activity
Figure 4 Severe cytokine release syndrome management algorithm.Patients with sCRS will initially receive tocilizumab, a
humanized mAb against IL-6 receptor. If the sCRS fails
to resolve, then cetuximab will be administered IV to
eliminate EGFRt CAR-modified T cells. Patients who show
worsening CRS within 12 hours or who fail to improve clin-
ically after 24 hours following administration of cetuximab
will be treated with IV and IP dexamethasone if clinically
indicated. Due to its potent and non-selective immunosup-
pressive activity, the administration of dexamethasone is
expected to result in the elimination of any remaining
CAR-modified T cells persisting in the patient following
treatment with cetuximab (Figure 4) [33-35].
Statistical methods
There are four planned dose levels of 4H11-28z/fIL-12/
EFGRt T cells: 3 × 105, 1 × 106, 3 × 106, and 1 × 106
4H11-28z/fIL-12/EFGRt T cells/kg. The first subject will
be treated at dose level 1 (3 × 105 4H11-28z/fIL-12/
EFGRt T cells/kg). At least one week will elapse from
the first patient’s T cell infusions before the second
patient is treated (on dose level 1) to allow for toxicity and
safetyassessment. Three subjects will be enrolled in cohort
I and followed for 30 days for safety assessments. If no
dose-limiting toxicity (DLT) is observed after all 3 subjectsge or requiring vasopressors OR
g supplemental oxygen or ventilatory support OR
and/or ECG changes OR
on EEG
mg/kg IV once
Clinical improvement < 24 hours
• Decreasing vasopressor dose OR
• Decreasing ventilatory support OR
• No further seizure activity
Observe
WorseningCRS (def. as above)
nically indicated
ment ≥ 24 hours
al improvement ≥ 24 hrs.
ne 10mg IV q6h
T cells: Dexamethasone 10mg IP q6hr
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jects will be enrolled at the same dose level (3 × 105
4H11-28z/fIL-12/EFGRt T cells/kg) with the addition of
cyclophosphamide. Cohorts will continue to be enrolled
and observed at sequentially increasing (predefined) dose
levels until 1 subject experiences a DLT. The MTD will
then be defined using traditional dose escalation rules. If 2
of the first 2 subjects have a DLT, the enrollment of a third
subject at the same dose level is not necessary. Similarly, if
2 of 4 subjects or 2 of 5 subjects have a DLT, it is not
necessary to enroll subsequent subjects at the same dose
level. This escalation/de-escalation will continue until the
following conditions are met: either 6 subjects have been
treated in the current cohort with no more than one DLT,
or 2 or more subjects have a DLT at the higher cohort.
When these conditions are met, the current dose level will
be considered the phase II dose.
The secondary aims of the study will be addressed by
descriptive exploratory statistical analyses, since the sample
size is not known in advance and there are no formal
hypotheses being tested. These analyses may include
descriptions of time patterns for continuous variables mea-
sured repeatedly, both on the individual level and aggre-
gated by dose level. Persistence of adoptively transferred
4H11-28z/fIL-12/EFGRt T cells will be assessed by RT-PCR
analysis and by FACS at different time points, as described
below, where we will obtain cell numbers and percentages
of CAR T cells compared to endogenous T cells in pre- and
post-treatment samples. Peripheral blood samples obtained
prior to T cell infusions will be compared to peripheral
blood samples 1-hour post T cell infusion and the samples
taken daily for 2 days and weekly thereafter for 8 weeks.
Samples will be analyzed using flow cytometry with a mAb
specific to the 4H11-28z CAR and by quantitative RT-PCR
analysis using primers and a probe targeting retroviral spe-
cific sequences. These peripheral blood samples will also be
utilized to assess expansion of endogenous tumor-targeted
T cells by infused 4H11-28z/fIL-12/EFGRt T cells by exclu-
sion of modified T cells by FACS sorting. The remaining T
cells will be analyzed for reactivity to tumor-specific targets
by ELISPOT and multiparameter flow cytometric analyses.
These experiments will provide a numerical count of
endogenous tumor-specific T cells, which will be monitored
and presented graphically.
Progression-free and overall survival will be described
by the Kaplan-Meier method. Patients’ best overall
radiographic response will be tabulated based on immune-
related response criteria [36].
Translational studies
(a) Assess in vivo persistence of genetically modified
T cells and characterize the endogenous tumor-specific
T cell expansion.Study design: Following infusion, the presence of
4H11-28z/fIL-12/EFGRt autologous T cells in
peripheral blood and ascites will be analyzed by
flow cytometry using a fluorochrome-conjugated
Armenian hamster mAb specific to the 4H11-28z
CAR, and by Quantitative Real Time-PCR analysis
using primers and probe targeting retroviral specific
sequences. To assess whether infusion of IL-12
secreting tumor-targeted T cells enhance proliferation
of endogenous tumor-specific T cells, peripheral blood
samples will be obtained from patients on day 3 prior
to infusion of modified T cells, and again 1 hour after
infusion. Samples of peripheral blood and peritoneal
lavage will also be drawn during follow-up. Briefly,
these samples will be drawn daily for 2 days after
T cell infusion, weekly thereafter for 8 weeks, and then
monthly for 6 months. T cells will be isolated from
these samples and sorted by FACS to exclude CAR
T cells. The resulting T cell samples will be analyzed
for reactivity to previously isolated tumor cells by
ELISPOT and multiparameter flow cytometric
analyses. In addition, we will assess phenotype of
CAR T cells and endogenous T cells for effector versus
memory cell markers in peripheral blood and ascites
samples.
(b) Examine the tumor microenvironment following
infusion of CAR T cells, including cytokine levels,
T cell suppressing ligands (PD-1 and CTLA-4), and
the presence of inhibitory cell types such as Tregs,
TAMs, and myeloid-derived suppressor cells.
Study design: These samples at the previously
discussed time points will be analyzed for levels of
various cytokines, including IL-12 and IFN-γ, along
with inhibitory cytokines such as IL-10 as measured
by Luminex 100IS technology. The presence of
inhibitory cell types such as Tregs, TAMs, and
myeloid-derived suppressor cells will be assessed
by flow cytometry using antibodies to appropriate
surface antigens associated with these cell types.
Lastly, flow cytometry will also be used to
characterize the levels of T cell suppressing ligands
such as PD-1 and CTLA-4 using antibodies for the
pre- and post-infusion samples.
Innovation
This trial offers several innovative features compared to
previous trials utilizing CARs for ovarian cancer. To
begin with, this trial incorporates a novel ovarian cancer
antigen, MUC-16ecto. Secondly, the trial is the first to
incorporate the addition of a cytokine to CARs allowing
delivery of an immunostimulatory agent to the tumor
microenvironment. In addition, the trial is the first to
incorporate the use of tricistronic vector allowing for
expression of three different genes, including EGFRt,
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CAR T cell administration, the combination of IP and IV
injections, is unique to this trial.
The 4H11 antibody from which the CAR was derived
has already been studied extensively against human
high-grade serous ovarian carcinomas in comparison to
normal tissues [23]. Tissue microarray slides representing
primary, metastatic, and recurrent tumors demonstrated
that the 4H11 antibody bound to high-grade serous ovar-
ian tumors with high specificity. Normal tissues such as
adult colon, rectum, ectocervix, small intestine, ovary,
liver, pancreatic ducts, spleen, kidney and skin (as well as
fetal heart, gallbladder, colon, small intestine, liver, rectum,
adrenal, thyroid, spleen, skin, bone, epididymis, brain,
lung, muscle, smooth muscle, kidney, eye, umbilical cord,
and placenta) did not stain with this antibody [23]. The
antibody for 4H11 did stain the luminal side of esophageal
glands and a few other areas, such as bronchial epithe-
lium, endocervical glands, and gastric glands, but only in
the cytoplasm [23]. Although MUC16 expression has been
found in the superficial epithelium at the corneal surface
of the eye, the antibody from which our CAR is derived
did not stain in the eye [14,23]. Therefore, due to the
limited staining of the 4H11 antibody on the extracellular
surface of normal cells and the high specificity to serous
ovarian tumors, the 4H11 CAR is a promising target for
use in a phase I clinical trial.
Given concern for the lack of in vivo persistence of
CAR T cells and the potential impairment by hostile
tumor microenvironment, we have further modified the
CAR T cells to secrete IL-12, a stimulatory cytokine that
can promote an anti-tumor response through multiple
mechanisms, including enhanced proliferation and
CD8+ T cell effector function. However, we acknowledge
the potential toxicity of IL-12 secreting CAR T cells. We
appreciate the importance of locoregional delivery of
IL-12 as a mechanism to limit toxicity since the CAR
will target the T cell to the site of tumor. In addition,
our preclinical studies indicate that the amounts of
IL-12 we observe both in vitro and in vivo mouse models
are lower than those observed by other groups [22,37,38].
Studies using both syngeneic and xenotransplant mouse
models have not demonstrated systemic toxicity, as
reported by others, and this has been confirmed by
pathology reports and formal toxicology studies [22].
Furthermore, in our in vivo model, we have found once
the antigen has been eradicated, IL-12 levels decreased to
nearly undetectable levels [22]. The IL-12 levels published
in humans trials (>2000 pg/mL) are 40-fold higher than
the values in our murine studies (<50 pg/mL), which is
anticipated to reduce deleterious effects [22,31,39].
Looking at the production of IL-12 in vitro, the levels
of IL-12 by CAR T cells are >5-fold lower compared
to CAR expressing flexi-IL12 or NFAT IL-12 from apublication from the NIH when we compared the
levels seen with this system compared to the amounts
described in that publication from the NIH [37].
Though previous studies have indicated toxicity with
IL-12, we believe that the lower levels associated with
this construct will correlate with less toxicity but still
provide necessary added benefit. The lower IL-12 levels
observed are likely due to the fact that the IL-12 is located
after an IRES element and that the construct is tricistro-
nic. Given the concern that there may be differences in
the sensitivity of mice versus humans on IL-12–mediated
systemic toxicity, we have included several safety measures
in our study design to mitigate the risks to patients.
Firstly, we will start at a much lower starting dose than
used in the leukemia CAR Tcell trials that are currently un-
derway at our institution (NCT00466531, NCT01860937).
The starting dose in our trial will be 3 × 105 CAR T cells/kg
compared to 3 × 106 CAR T cells/kg in the leukemia trials.
Secondly, we have incorporated an elimination gene
in the vector. Thirdly, our experience of CAR technology
in leukemia has enabled us to develop a comprehensive
algorithm that outlines the proposed treatment for patients
who encounter CAR T cell toxicity. If the patient fulfills
the criteria for sCRS, then the patient will initially be dosed
with tocilizumab. However, if the patient does not improve
or develops worsening CRS, the EGFRt elimination gene
can be activated through administration of IV cetuximab.
In the event of further deterioration, the presence of the IP
catheter means that patients will also be able to receive
dexamethasone IP as well as IV.
We propose that split IV/IP route dosing is appropriate
for 2 reasons: (1) IV dosing addresses metastatic disease
outside of the peritoneum, and (2) IP administration has
been shown in our murine models to have more long-term
efficacy compared to IV administration. The 1 to 3 day
interval between the IV and IP T cell infusions will permit
us to monitor patients for any toxicity related to the CAR
T cells before proceeding to the first in-human IP adminis-
tration of CAR T cells. Additionally, we have performed
toxicology studies in which half the dose was given IV and
half IP in the same group of mice. In this study, complete
necropsy and blood work has been completed. The results
indicate no adverse events or toxic lesions in an immune
competent syngeneic mouse model after CAR administra-
tion 2 weeks post-tumor injection at a dose of 2.5 million
CAR T cells IV followed by next day delivery of 2.5 million
CAR Tcells IP (data not shown).
Discussion
Adoptive immunotherapy with CAR autologous T cells
is a new approach in the treatment of advanced ovarian
cancer allowing for targeted antitumor activity with the
hope of providing prolonged disease control through
potential modulation of the endogenous immune system.
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in patients with B-cell leukemias. Recently, our group
published the successful results of a phase I adult ALL trial
targeting CD19+ tumors using (19-28z) CAR T cells [29].
However, trials utilizing CAR therapy in ovarian cancer are
limited and to date have not been successful [40].
Our goal is to determine the safety and feasibility of IV
and IP infusion of autologous 4H11-28z/fIL-12/EGFRt T
cells with or without prior high-dose cyclophosphamide.
Ultimately, we hope this approach will lead to in vivo
persistence of adoptively transferred 4H11-28z/fIL-12/
EFGRt T cells allowing for anti-tumor efficacy and
further modulation of tumor microenvironment, such
that the patient develops increased progression-free
survival. Choosing the appropriate target antigen is
one of the initial steps in engineering an improved CAR
to accomplish these objectives. MUC16ecto is the retained
extracellular portion of epithelial ovarian carcinoma,
which is a TAA that the CAR targets. The antibody from
which the CAR is derived has been extensively tested in
human ovarian models and normal tissues, showing high
specificity with low background levels [23]. We use CD28
as a co-stimulatory domain along with CD3ζ trans
membrane protein in a gammaretroviral backbone, which
acts as a potent amplifying signal for CD19 specific CARs
in the clinical setting. Therefore, we incorporated a similar
design in the ovarian CAR.
This clinical trial is unique in numerous other aspects
compared to previous trials, mainly due to the incorpor-
ation of CAR T cells that secrete IL-12, allowing for the
favorable modulation of the tumor microenvironment and
the endogenous immune system. Other novel features
include a different target antigen, MUC-16ecto, the tricis-
tronic nature of the construct, and the inclusion of IP
administration of CAR T cells. Though numerous CARs
have been designed to target TAAs, including α-folate
receptor, NKG2D, and mesothelin, only the results of the
trial utilizing the α-folate receptor have been published,
and they show a lack of CAR T cell persistence [40-43].
We hope to overcome this limitation by the addition of
IL-12 to allow for enhanced persistence, which has been a
noted feature in orthotopic human ovarian mouse
models [22]. A recent publication from the NIH using
TILs genetically engineered with an inducible IL-12
for metastatic melanoma shows the utility of IL-12 in solid
tumors allowing for the absence of IL-2 administration and
lower cell doses than trials using conventional TILs [39].
However, the authors discussed toxicities observed at
higher doses of 0.3 to 3 × 109 NFAT.IL-12 cells, including
hepatic dysfunction, high fevers and periodic hemodynamic
instability, which they attributed to the IL-12. In addition,
they mentioned the lack of proliferation and persistence of
IL-12 secreting TILs. Our pre-clinical studies indicate that
IL-12 secreting CAR T cells show improved proliferationcompared to non-IL-12 secreting CAR T cells in vitro and
show enhanced persistence in murine tumor models [22].
Furthermore, as supported by our preclinical studies, we
believe that our approach will be associated with less IL-12
related toxicity. We anticipate lower IL-12 levels for 3
reasons: 1) the IL-12 gene follows an IRES element,
2) the tricistronic nature of the construct, and 3) the
lower CAR T cell doses used. As an added safety feature
we have incorporated an elimination gene. Moreover,
patients will be closely monitored in the inpatient setting
during and following treatment with CAR T cells.
Enrollment on the study will be staggered both within
and between cohorts to allow for toxicity assessment.
Adoptive immunotherapy has shown promise in
hematologic malignancies. Recently, we published the
successful results of phase I adult ALL trial targeting
CD19+ tumors using (19-28z) CAR T cells [29]. The
surge for better treatment continues as CAR-T therapy
enters the solid tumor arena. We propose a novel phase I
ovarian cancer trial targeting MUC-16ecto using 4H11
antibody. It is highly specific for epithelial ovarian
carcinomas without being significantly expressed on
other normal tissues. Carrying forward the tradition
of armored CARs, we incorporated IL-12 transgene
into our vector design to alter the tumor milieu and
educate immune cells within the hostile tumor micro-
environment to fight against the tumor along with effector
T cells and CARs while making them persist longer. Safety
has been a major issue of concern while using CAR T
therapy over the years. We incorporated EGFRt gene into
the construct, which will cause the cells to be eliminated
upon administration of cetuximab, thereby creating a
“safety switch”. Intraperitoneal administration of CAR T
therapy along with conventionally used IV infusion pre-
sents a unique technique, as it ensures tumor killing within
the peritoneum, along with any distant metastasis.
Conclusions
In summary, we propose that this clinical trial using
CAR technology for patients with advanced recurrent
MUC16ecto+ ovarian, fallopian tube, or primary peritoneal
cancer will be beneficial overall compared to the potential
risks. Given the natural history of advanced-stage ovarian
cancer, characterized by multiple recurrences and
invariable development of chemotherapy-refractory disease,
alternative therapies are required. Though numerous
clinical trials have shown utility of CAR T cell therapy in
hematological malignancies, it remains unclear whether
such an approach would have the same efficacy in solid
tumors. We developed this trial with particular attention
to address potential limitations of the few other unsuc-
cessful CAR trials in solid tumors. The main principle dif-
ference with this trial compared to others is the concept
of using the CAR T cell not only as a mechanism to
Koneru et al. Journal of Translational Medicine  (2015) 13:102 Page 10 of 11enhance tumor-directed cytolysis but also to act as a deliv-
ery tool of an agent that can further modulate the tumor
microenvironment. Localized delivery of IL-12 to the
tumor microenvironment can enhance the endogenous
immune system and allow for further participation in
tumor elimination. While engineering of CAR-expressing
T cells is a relatively novel field, particularly with
respect to solid malignancies, if successful, this approach
could eventually be extended to a wide variety of other
tumor types.
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